---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-003178"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2022-02-18T23:59:59+00:00"
generated_at: "2026-06-27T06:35:31.771849+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics promotes Garry Neil to CEO and Chris Sullivan to CFO, replaces Cola and Greenway

## Summary
- Garry Neil appointed CEO from CSO; base salary $475K/yr, option for 1M shares vesting 4 years.
- Chris Sullivan appointed CFO from CAO; base salary $350K/yr, $50K bonus, option for 400K shares.
- Former CEO Michael Cola and CFO Schond Greenway terminated effective Feb 14, 2022.
- Neil serves as Chairman of Arena Pharmaceuticals (ARNA), a ~$6B Nasdaq biotech.
- Sullivan previously helped raise ~$80M in gross proceeds as interim CFO.

## SEC filing metadata
- accession: 0001628280-22-003178
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2022-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/avtx-20220214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-003178
- JSON: https://secwatch.observer/filing/0001628280-22-003178.json
- Plain text: https://secwatch.observer/filing/0001628280-22-003178.txt

## Key facts
- Executive change
  Christopher Sullivan was appointed as Chief Financial Officer at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm
- Executive change
  Garry A. Neil was appointed as President and Chief Executive Officer at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022003178/0001628280-22-003178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.